Tirzepatide (Mounjaro/Zepbound, Eli Lilly) is a dual GIP+GLP-1 receptor agonist — the first approved peptide to co-activate both incretin receptors simultaneously. Native GIP (glucose-dependent insulinotropic polypeptide) primarily acts on pancreatic beta cells and adipose tissue; native GLP-1 acts on the pancreas, brain, gut, and liver. Tirzepatide's dual mechanism produces additive effects on insulin secretion, appetite suppression, and fat metabolism that exceed GLP-1 monotherapy.
| Week | Dose | Notes |
|---|---|---|
| 1–4 | 2.5 mg | Initiation dose |
| 5–8 | 5 mg | First escalation |
| 9–12 | 7.5 mg | Intermediate dose |
| 13–16 | 10 mg | SURPASS Phase 3 primary dose |
| 17–20 | 12.5 mg | Second-highest dose |
| 21+ | 15 mg | Maximum dose (SURMOUNT programme) |
SURMOUNT-1 (NCT04184622): At 72 weeks, 15 mg tirzepatide produced 20.9% mean body weight reduction — the first GLP-class compound to exceed 20% in a Phase 3 trial, previously achieved only by Retatrutide in Phase 2. SURMOUNT-2 in adults with type 2 diabetes showed 13.4% weight reduction at 72 weeks with 15 mg dosing.
QSC Tirzepatide is supplied in 5 mg vials. Add 1 mL BAC water to produce a 5 mg/mL solution. For a 2.5 mg dose: draw 0.5 mL. For a 5 mg dose: draw 1.0 mL. Store reconstituted solution at 2–8°C for up to 28 days. Protect from light.
| Semaglutide 2.4 mg | Tirzepatide 15 mg | Retatrutide 12 mg | |
|---|---|---|---|
| Max weight loss (Phase 2/3) | ~15% | ~21% | ~23% |
| Receptors targeted | GLP-1R | GLP-1R + GIPR | GLP-1R + GIPR + GCGR |
| Once weekly | Yes | Yes | Yes |
This page is for educational and research purposes only. All products sold by QSC are labelled for research use only and are not intended for human consumption. Nothing on this page constitutes medical advice.